BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 34166499)

  • 1. Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients.
    Mazzola A; Todesco E; Drouin S; Hazan F; Marot S; Thabut D; Varnous S; Soulié C; Barrou B; Marcelin AG; Conti F
    Clin Infect Dis; 2022 Mar; 74(6):1093-1096. PubMed ID: 34166499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls.
    Hamm SR; Møller DL; Pérez-Alós L; Hansen CB; Pries-Heje MM; Heftdal LD; Hasselbalch RB; Fogh K; Madsen JR; Almagro Armenteros JJ; Knudsen AD; Poulsen JR; Frikke-Schmidt R; Hilsted LM; Sørensen E; Ostrowski SR; Harboe ZB; Perch M; Sørensen SS; Rasmussen A; Bundgaard H; Garred P; Iversen K; Nielsen SD
    Front Immunol; 2022; 13():832501. PubMed ID: 35281023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral and cellular immune responses to the SARS-CoV-2 BNT162b2 vaccine among a cohort of solid organ transplant recipients and healthy controls.
    Yanis A; Haddadin Z; Spieker AJ; Waqfi D; Rankin DA; Talj R; Thomas L; Birdwell KA; Ezzell L; Blair M; Eason J; Varjabedian R; Warren CM; Nochowicz CH; Olson EC; Simmons JD; Yoder S; Guy M; Thomsen I; Chappell JD; Kalams SA; Halasa NB
    Transpl Infect Dis; 2022 Feb; 24(1):e13772. PubMed ID: 34905653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients.
    Erol Ç; Yanık Yalçın T; Sarı N; Bayraktar N; Ayvazoğlu Soy E; Yavuz Çolak M; Azap Ö; Arslan H; Haberal M
    Exp Clin Transplant; 2021 Dec; 19(12):1334-1340. PubMed ID: 34951350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
    Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.
    Bárczi E; Varga V; Nagy A; Eszes N; Jáky-Kováts Z; Müller V; Bohács A
    Immun Inflamm Dis; 2022 Aug; 10(8):e646. PubMed ID: 35894705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early humoral immune response to two doses of severe acute respiratory syndrome coronavirus 2 vaccine in a diverse group of solid organ transplant candidates and recipients.
    Huang HJ; Yi SG; Mobley CM; Saharia A; Bhimaraj A; Moore LW; Kloc M; Adrogue HE; Graviss EA; Nguyen DT; Eagar TN; Jones SL; Ankoma-Sey V; MacGillivray TE; Knight RJ; Gaber AO; Ghobrial RM
    Clin Transplant; 2022 May; 36(5):e14600. PubMed ID: 35083796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of two doses of SARS-CoV-2 mRNA vaccine in kidney transplant recipients with low-dose rituximab.
    Takai S; Nishida H; Ito H; Fukuhara H; Nawano T; Narisawa T; Kanno H; Yagi M; Yamagishi A; Sakurai T; Naito S; Kato T; Morikane K; Tsuchiya N
    Int J Urol; 2022 Nov; 29(11):1279-1286. PubMed ID: 35863901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study.
    Rozen-Zvi B; Yahav D; Agur T; Zingerman B; Ben-Zvi H; Atamna A; Tau N; Mashraki T; Nesher E; Rahamimov R
    Clin Microbiol Infect; 2021 Aug; 27(8):1173.e1-1173.e4. PubMed ID: 33957273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.
    Reindl-Schwaighofer R; Heinzel A; Mayrdorfer M; Jabbour R; Hofbauer TM; Merrelaar A; Eder M; Regele F; Doberer K; Spechtl P; Aschauer C; Koblischke M; Paschen C; Eskandary F; Hu K; Öhler B; Bhandal A; Kleibenböck S; Jagoditsch RI; Reiskopf B; Heger F; Bond G; Böhmig GA; Strassl R; Weseslindtner L; Indra A; Aberle JH; Binder M; Oberbauer R
    JAMA Intern Med; 2022 Feb; 182(2):165-171. PubMed ID: 34928302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine.
    Fonseca MHG; Pinto ACMD; Silva MFS; de Melo ACL; Vasconcelos GS; Dos Santos ER; de Carvalho Araújo FM; de Andrade LOM
    Emerg Infect Dis; 2022 Jun; 28(6):1237-1240. PubMed ID: 35421324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the SARS-CoV-2 mRNA vaccine in lung transplant recipients: a possible trigger of rejection.
    Goda Y; Nakajima D; Tanaka S; Yamada Y; Yutaka Y; Unagami K; Yoshikawa M; Egawa H; Date H
    Gen Thorac Cardiovasc Surg; 2023 Apr; 71(4):251-257. PubMed ID: 36289168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic response of mRNA SARS-CoV-2 vaccination in adolescent kidney transplant recipients.
    Crane C; Phebus E; Ingulli E
    Pediatr Nephrol; 2022 Feb; 37(2):449-453. PubMed ID: 34522992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular and humoral immune responses after a third dose of SARS-CoV-2 mRNA vaccine in lung transplant recipients in Japan.
    Ui M; Hirama T; Akiba M; Honda M; Kikuchi T; Okada Y
    Vaccine; 2023 Jul; 41(31):4534-4540. PubMed ID: 37328349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients.
    Hoffman TW; Meek B; Rijkers GT; van Kessel DA
    Transpl Immunol; 2022 Jun; 72():101599. PubMed ID: 35390480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.
    Bensouna I; Caudwell V; Kubab S; Acquaviva S; Pardon A; Vittoz N; Bozman DF; Hanafi L; Faucon AL; Housset P
    Am J Kidney Dis; 2022 Feb; 79(2):185-192.e1. PubMed ID: 34508833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of mRNA Vaccine Immunogenicity in Solid Organ Transplant Recipients.
    Tsoutsoura P; Xagas E; Roussos S; Hatzakis A; Gourzi P; Boletis IN; Marinaki S
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374279
    [No Abstract]   [Full Text] [Related]  

  • 18. Detectable plasma severe acute respiratory syndrome coronavirus 2 spike antigen is associated with poor antibody response following third messenger RNA vaccination in kidney transplant recipients.
    Karaba AH; Swank Z; Hussain S; Chahoud M; Durand CM; Segev DL; Robien MA; Heeger PS; Larsen CP; Tobian AAR; Walt DR; Werbel WA
    Transpl Infect Dis; 2024 Jun; 26(3):e14281. PubMed ID: 38618895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis.
    Verleye A; Wijtvliet V; Abrams S; Hellemans R; Bougrea R; Massart A; Pipeleers L; Wissing KM; Ariën KK; De Winter BY; Van Damme P; Abramowicz D; Ledeganck KJ
    Nephrol Dial Transplant; 2022 Jul; 37(8):1566-1575. PubMed ID: 35544087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship Between Immune Response to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines and Development of Breakthrough Infection in Solid Organ Transplant Recipients: The CONTRAST Cohort.
    Bonazzetti C; Tazza B; Gibertoni D; Pasquini Z; Caroccia N; Fanì F; Fornaro G; Pascale R; Rinaldi M; Miani B; Gamberini C; Morelli MC; Tamé M; Busutti M; Comai G; Potena L; Borgese L; Salvaterra E; Lazzarotto T; Scudeller L; Viale P; Giannella M;
    Clin Infect Dis; 2023 May; 76(10):1761-1767. PubMed ID: 36636955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.